Celldex Q4 2024 Earnings Report
Key Takeaways
Celldex reported a total revenue of $1.2 million and a net loss of $47.1 million, or ($0.71) per share, for the fourth quarter of 2024. Cash, cash equivalents and marketable securities were $725.3 million as of December 31, 2024. The company believes its current cash position is sufficient to fund operations through 2027.
Barzolvolimab Phase 3 studies in CSU are actively enrolling patients.
Initiated two new programs: barzolvolimab in atopic dermatitis and CDX-622 in clinic.
Expects 2025 will be a year of continued execution across the pipeline.
Cash, cash equivalents and marketable securities as of December 31, 2024 were $725.3 million.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.
Positive Outlook
- Cash position sufficient to fund operations through 2027.